TNK in Acute Ischemic Stroke [SPOTRIAS]

Completed

Phase N/A Results

Summary of Purpose

To determine the appropriate dose of tenecteplase (TNK-TPA), a form of tissue plasminogen activator, in patients with acute ischemic stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 15 April 2008.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • National Institute for Neurological Disorders and Stroke, NIH

Trial Design

Pilot, dose-escalation safety study.

Contacts

Not available